LONDON and GAITHERSBURG, Md., May  21, 2026  (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T

AUTL

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

Autolus Reports Promising Obe-Cel Data Ahead of ASCO 2026 Presentation

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>LONDON and GAITHERSBURG, Md., May  21, 2026  (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Autolus Therapeutics has announced a promising abstract for its therapy obe-cel, showing a 59% response rate and a median duration of response of 42.6 months in patients with B-ALL and extramedullary disease. This upcoming presentation at the ASCO Annual Meeting could attract investor interest and showcase obe-cel as a viable treatment for a challenging patient demographic.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Autolus presents abstract on obe-cel at ASCO 2026.</li><li>Obe-cel shows 59% response rate in B-ALL with EMD.</li><li>Median duration of response for EMD patients is 42.6 months.</li><li>Positive benefit-risk profile noted for obe-cel treatment.</li><li>Session scheduled on May 30, with detailed findings.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Memorial Sloan Kettering Cancer Center (N/A)</strong>: Collaboration in research could enhance Autolus&#039;s reputation in clinical results.</li></ul>
  </section>

  <section data-block="category">
    <h3>Industry News</h3>
    <p>This falls under &#039;Industry News&#039; due to the significant implications of new clinical data on treatment options within the oncology sector and the potential for impacting patient outcomes positively.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Presentation of obe-cel research at ASCO could drive investor interest.</li><li>High response rates may attract partnerships or increased market adoption.</li><li>Regulatory updates post-ASCO can impact valuation significantly.</li><li>Continued positive clinical trial results could attract analysts&#039; upgrades.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Overall response rate for obe-cel in EMD patients is 59%.</li><li>Median duration of response for EMD patients is 42.6 months.</li><li>Data presented at ASCO Annual Meeting from May 29 to June 2, 2026.</li><li>Abstract Number: 6517, presentation on May 30, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>AUTL is likely to experience upward momentum as positive data fuels investor confidence in obe-cel.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">LONDON and GAITHERSBURG, Md., May  21, 2026  (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AUTL">AUTL</a>), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, announces the online publication of an abstract submitted to the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago, Illinois.</p>  <p align="justify">"Data to be presented at the upcoming ASCO Annual Meeting provides insight into the use of obe-cel in patients with B-ALL and extramedullary disease (EMD), which is typically associated with shorter median and long-term survival compared to marrow-only relapse. With an overall response rate of 59% and a median duration of response (mDOR) of 42.6 months for patients with EMD, obe-cel may be considered as a potential treatment option for this difficult to treat population of patients," said Matthias Will, MD, Autolus Chief Development Officer.</p>  <p align="justify"><strong><u>Abstract 6517</u></strong><br></br><strong>Title</strong>: The effect of obecabtagene autoleucel (obe-cel) on adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and extramedullary disease (EMD).<br></br><strong>Session Type and Track: </strong>Rapid Oral Abstract: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant. <br></br><strong>Session Date and Time</strong>: May 30, 2026; 1:15 – 2:45PM CDT<br></br><strong>Session Room</strong>: E450a<br></br><strong>Abstract Number</strong>: 6517<br></br><strong>Presentation time:</strong> 2:27 – 2:33pm CDT<br></br><strong>Presenting Author</strong>: Jae Park, MD, Director, Adult ALL Program &#x7C; Acting Chief, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center, New York, NY, USA</p>  <p align="justify"><strong>Summary:</strong> A post-hoc analysis of the Phase Ib/II FELIX study (NCT04404660) was conducted, evaluating the efficacy and safety of obe-cel in patients with relapsed or refractory (r/r) B-ALL, by EMD status at lymphodepletion (LD). Following LD, adults with r/r B-ALL received obe-cel using a tumor burden-guided dosing strategy to minimize toxicity. Obe-cel treatment demonstrated favorable response and safety outcomes in patients with and without EMD in the FELIX trial. Of 127 obe-cel infused patients, 27 (21%) had EMD at LD. Among responders, duration of response in patients with EMD was 42.6 months, and the overall remission rate was 59%. Overall, these findings suggest a positive benefit–risk profile for obe-cel, including for patients with adverse risk features, specifically EMD at LD.</p>  <p align="justify"><strong>About Autolus Therapeutics plc</strong><br></br>Autolus Therapeutics plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AUTL">AUTL</a>) is a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has a marketed therapy, AUCATZYL&#xAE;, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=jkFOuaI4-7fa2uoYsVXC40fOs55M4Po5sv3-gygYaeFQaMMooLH1pawcdI7gLYDMEnJsHw6A6IbOnggAyKrrYKBnLZJXc5_D3VRBCICP5Ak=" rel="nofollow" target="_blank">www.autolus.com</a>.</p>  <p align="justify"><strong>Contact:</strong></p>  <p align="justify">Amanda Cray<br></br>+1 617-967-0207<br></br><a href="https://www.globenewswire.com/Tracker?data=aywkzqG9NnRgGsQV3iJV-N2rP1qQFQTBPXyOjnDOTtOqM_cdf37BsV8GqfncpcxZ3xC52dNHQ6BIlTkldv5kUC2Lag6S7oR8cNqfNBsgYEc=" rel="nofollow" target="_blank">a.cray@autolus.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcyNDE0NSM3NjE0MDAxIzIwOTk2MzA="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZDEwZWY2MGUtMTkwNS00MTZiLTk5OGQtMmJjMmRkOGFhZDRiLTExMTEyMDEtMjAyNi0wNS0yMS1lbg==/tiny/Autolus-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/680b5e1a-9aba-4e38-b280-e43036561ef1"><img src="https://ml.globenewswire.com/media/680b5e1a-9aba-4e38-b280-e43036561ef1/small/picture1-png.png" border="0" width="150" height="35" alt="Primary Logo"></img></a></p>

Autolus Therapeutics has announced a promising abstract for its therapy obe-cel, showing a 59% response rate and a median duration of response of 42.6 months in patients with B-ALL and extramedullary disease. This upcoming presentation at the ASCO Annual Meeting could attract investor interest and showcase obe-cel as a viable treatment for a challenging patient demographic.

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Industry News

Related News